Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases.
The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia.
The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs.
It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products.
Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
|IPO Date||Nov 11, 2015|
|CEO||G. Andre Turenne|
75 Sidney St
Cambridge, Massachusetts 02139-4134
|Phone||857 259 5340|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Michael J. Higgins M.B.A.||Interim Chief Executive Officer, President and Chairman|
|Dr. Glenn F. Pierce M.D., Ph.D.||Independent Director, Interim Chief Scientific Officer and Chief Medical Officer|
|Robert W. Hesslein||Senior Vice President and General Counsel|
|G. Andre Turenne||Advisor|
|Dr. Steven M. Paul M.D.||Executive Science Advisor and Director|
|Dr. Krystof Bankiewicz M.D., Ph.D.||Founder|
|Dr. Guangping Gao||Founder|
|Dr. Mark A. Kay M.D., Ph.D.||Founder|
|Dr. Phillip D. Zamore||Founder|
|Julie Burek||Principal Financial and Accounting Officer|
Latest SEC Filings
|Nov 30, 2021||4||Statement of changes in beneficial ownership of securities|
|Nov 30, 2021||3||Initial statement of beneficial ownership of securities|
|Nov 19, 2021||8-K||Current report|
|Nov 2, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Nov 2, 2021||8-K||Current report|
|Oct 22, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Oct 6, 2021||8-K||Current report|
|Aug 9, 2021||10-Q||Quarterly report [Sections 13 or 15(d)]|
|Aug 9, 2021||8-K||Current report|
|Jul 12, 2021||SC 13G/A||Statement of acquisition of beneficial ownership by individuals|
|View All SEC Filings|